Sign In
Buy MRNA
$47.44
-4.15 (-8.04%)
At Close: Jun 05, 2026
Better Buy: Moderna vs Axsome
05:30am, Thursday, 22'nd Dec 2022
Revenue prospects look promising for both of these biotech companies.
Could This Opportunity Make Moderna a Hot Buy Again?
09:37am, Wednesday, 21'st Dec 2022
Merck and Moderna recently announced positive results from a trial involving their personalized cancer vaccine.
Jefferies upgrades Moderna stock, raises price target
04:35pm, Monday, 19'th Dec 2022
Yahoo Finance Live anchors Seana Smith and Pras Subramanian break down the action surrounding Moderna after Jefferies analysts upgraded its stock and price target.
Moderna shifts focus to developing cancer vaccinations
04:33pm, Monday, 19'th Dec 2022
Michael Yee of Jefferies joins 'Closing Bell' to discuss Moderna's shift away from Covid-focused pharmaceuticals toward PCV cancer vaccination, the market size for personalized cancer vaccines and the
Moderna's (MRNA) BA.1 Omicron Booster Gets CHMP Nod for Kids
12:02pm, Monday, 19'th Dec 2022
The CHMP recommends authorizing Moderna's (MRNA) bivalent COVID-19 booster vaccine, targeting the Omicron BA.1 subvariant, for young children aged between six and 11 years.
Moderna Stock Is Upgraded on Growth Opportunities Not Related to Covid
09:14am, Monday, 19'th Dec 2022
Jefferies analyst Michael Yee upgrades shares of Moderna to Buy from Hold, and boosts the price target to $275.
Are These Multibillion-Dollar Vaccine Stocks Still a Buy?
09:15am, Sunday, 18'th Dec 2022
Moderna and Merck are up on the news regarding their melanoma cancer vaccine.
5 No-Brainer Stocks to Buy Before 2023
05:15am, Sunday, 18'th Dec 2022
These stocks are dirt cheap today. But low valuations may not last for long.
3 Beaten-Down Stocks That Could Explode Higher in 2023
09:15am, Saturday, 17'th Dec 2022
These stocks could have significant upside opportunities ahead.
3 Top Stocks to Buy Before 2023
06:33am, Saturday, 17'th Dec 2022
Here are some great bargains for long-term investors as we approach the end of the year.
Moderna's Next $20B Franchise - Learning From Merck's Keytruda
04:00pm, Friday, 16'th Dec 2022
Keytruda has proved to be MRK's leading sales driver, projected to contribute a significant 35.38% of FY2022 revenues at $20.9B. Given the early clinical success of MRNA and Keytruda combo, we reckon
Moderna Comes Alive On Good Performance From Pipeline, Please Try Again
01:50pm, Friday, 16'th Dec 2022
Moderna, Inc. lauded results from a clinical study readout. The large magnitude of the positive trend in a deadly cancer is an encouraging sign.
Is Moderna a Good Stock to Buy Right Now?
05:19am, Thursday, 15'th Dec 2022
Recent results suggest the company's cancer vaccine candidate can succeed where others have failed.
Is Moderna Stock A Buy Following Skin Cancer Vaccine Progress?
05:00am, Thursday, 15'th Dec 2022
Moderna stock rallied by close to 20% in Tuesday's trading, after it announced positive results from mid-stage trials for a messenger RNA-based vaccine for skin cancer patients that it is developing w
Moderna (MRNA) Up 20% on Upbeat Data From Cancer Jab Study
12:47pm, Wednesday, 14'th Dec 2022
Data from a mid-stage study showed that Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda reduces the risk of recurrence/death by 44% in melanoma patients.
